Reporting Setting in Psychedelic Clinical Trials

The Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) 2025 Guidelines were developed through an international Delphi consensus process to identify the most important extra-pharmacological factors influencing psychedelic clinical trials. These factors – commonly referred to as “(mind)set and setting” – include the physical, social contexts in which psychedelic substances are administered. The ReSPCT Guidelines provide a standardized framework for reporting these contextual variables, aiming to support transparency, comparability, and rigour in psychedelic research. Researchers, clinicians, and trial designers are invited to use the guidelines, and explanatory materials to improve study design and reporting across the field.

Reference: Pronovost-Morgan C, Greenway KT, Roseman L & The ReSPCT Experts. An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nature Medicine. 2025. https://www.nature.com/articles/s41591-025-03685-9